PRS:四氯十氧阴离子(TCDO)复合物滴注负压伤口疗法加速伤口愈合

2021-08-23 MedSci原创 MedSci原创

负压伤口疗法(NPWT)可促进肉芽组织的形成,增加局部血流量,减少组织水肿和清除渗出物,是一项标准的加速伤口愈合的方法。局部创面溶液滴注NPWT的结合为创面愈合提供了进一步的好处。

负压伤口疗法(NPWT)可促进肉芽组织的形成,增加局部血流量,减少组织水肿和清除渗出物,是一项标准的加速伤口愈合的方法。局部创面溶液滴注NPWT的结合为创面愈合提供了进一步的好处。

既往的研究表明TCDO可显著降低糖尿病足溃疡伤口的严重程度评分、感染、炎症和坏死组织的形成,从而促进肉芽组织的形成。

该前瞻性随机对照试验临床研究文章发表于2021年8月刊prs。按照伤口面积≥4cm2、伤口深度≥10mm、创面愈合时间预计≥15天等标准,最终纳入48名成年患者。

这项研究旨在于比较NPWTi(TCDO滴注+负压伤口疗法)与NPWT(标准负压伤口疗法)的疗效区别。

图1.来源截图

在研究前,研究人员对患者进行TCDO溶液皮肤过敏试验后,采用连续15天的负压伤口疗法治疗。两组的负压均设置为-125 mmHg,均每3天更换一次敷料。

两组患者之间年龄、性别、基础疾病、当前吸烟情况与否、创面的解剖位置、原因和伤口手术次数均没有统计学差异。
这些患者的创面分别来源于截瘫患者的压疮、糖尿病足部溃疡、创伤后的伤口、坏死性筋膜炎和肿瘤手术术后复杂的创面缺损伴皮瓣重建失败情况。

表1 患者特征

结果表明,TCDO复合灌注负压创面疗法在伤口表面积、深度和体积方面显著加速伤口愈合。

表2 创面面积及缩小程度

表3 创面深度及降低程度

表4创面体积及减小程度

组织学培养结果显示,两组均没有明显的规律改变,两组之间也没有统计学差异。组织病理学结果显示,NPWT组较NPETi组的新生毛细血管数量更少,水肿的间质细胞更多。

图2 伤口大小的改变情况图

研究结果表明,TCDO复合灌注负压创面疗法在伤口表面积、深度和体积方面显著加速伤口愈合。而在NPWTi组和单独NPWT组之间,细菌减少没有统计学上的显著差异。

将TCDO与NPWT结合使用主要是为了消除微生物,但NPWTi对细菌减少的益处尚不确定。虽然NPWTi的益处已经得到证明,但注入的解决方案仍不确定。
a.TCDO灌注的最佳停留时间:既往研究的适当范围在10-20分钟
b.TCDO的最佳灌注频率:既往研究为2-24次每天
c.TCDO的最佳灌注量:观察泡沫的饱和度

因此,研究人员认为,TCDO灌注在标准负压创面治疗中可作为一种辅助治疗

 

原始文献:

Burusapat Chairat,Sringkarawat Sophilak,Efficacy of Negative-Pressure Wound Therapy with Tetrachloro decaoxygen-Anion Complex Instillation Compared with Standard Negative-Pressure Wound Therapy for Accelerated Wound Healing: A Prospective, Randomized, Controlled Trial.[J] .Plast Reconstr Surg, 2021, undefined: undefined.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2083864, encodeId=5380208386414, content=<a href='/topic/show?id=344b1e1990b' target=_blank style='color:#2F92EE;'>#TCD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17199, encryptionId=344b1e1990b, topicName=TCD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 24 06:37:00 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910665, encodeId=feb81910665c1, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Dec 01 10:37:00 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179521, encodeId=edad11e95213a, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=291d6155851, createdName=ms4000000294901317, createdTime=Sat Jan 01 12:06:23 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669084, encodeId=fdd716690842c, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Mon Aug 01 22:37:00 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309915, encodeId=f9141309915b3, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 25 12:37:00 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2021-11-24 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=2083864, encodeId=5380208386414, content=<a href='/topic/show?id=344b1e1990b' target=_blank style='color:#2F92EE;'>#TCD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17199, encryptionId=344b1e1990b, topicName=TCD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 24 06:37:00 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910665, encodeId=feb81910665c1, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Dec 01 10:37:00 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179521, encodeId=edad11e95213a, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=291d6155851, createdName=ms4000000294901317, createdTime=Sat Jan 01 12:06:23 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669084, encodeId=fdd716690842c, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Mon Aug 01 22:37:00 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309915, encodeId=f9141309915b3, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 25 12:37:00 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2083864, encodeId=5380208386414, content=<a href='/topic/show?id=344b1e1990b' target=_blank style='color:#2F92EE;'>#TCD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17199, encryptionId=344b1e1990b, topicName=TCD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 24 06:37:00 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910665, encodeId=feb81910665c1, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Dec 01 10:37:00 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179521, encodeId=edad11e95213a, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=291d6155851, createdName=ms4000000294901317, createdTime=Sat Jan 01 12:06:23 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669084, encodeId=fdd716690842c, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Mon Aug 01 22:37:00 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309915, encodeId=f9141309915b3, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 25 12:37:00 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2022-01-01 ms4000000294901317

    好文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2083864, encodeId=5380208386414, content=<a href='/topic/show?id=344b1e1990b' target=_blank style='color:#2F92EE;'>#TCD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17199, encryptionId=344b1e1990b, topicName=TCD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 24 06:37:00 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910665, encodeId=feb81910665c1, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Dec 01 10:37:00 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179521, encodeId=edad11e95213a, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=291d6155851, createdName=ms4000000294901317, createdTime=Sat Jan 01 12:06:23 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669084, encodeId=fdd716690842c, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Mon Aug 01 22:37:00 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309915, encodeId=f9141309915b3, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 25 12:37:00 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2022-08-01 kzlchina
  5. [GetPortalCommentsPageByObjectIdResponse(id=2083864, encodeId=5380208386414, content=<a href='/topic/show?id=344b1e1990b' target=_blank style='color:#2F92EE;'>#TCD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17199, encryptionId=344b1e1990b, topicName=TCD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Nov 24 06:37:00 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910665, encodeId=feb81910665c1, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Dec 01 10:37:00 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179521, encodeId=edad11e95213a, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=291d6155851, createdName=ms4000000294901317, createdTime=Sat Jan 01 12:06:23 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669084, encodeId=fdd716690842c, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Mon Aug 01 22:37:00 CST 2022, time=2022-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309915, encodeId=f9141309915b3, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Aug 25 12:37:00 CST 2021, time=2021-08-25, status=1, ipAttribution=)]

相关资讯

Br J Surg:负压伤口疗法作为儿童小面积热烧伤辅助疗法的有效性

负压伤口疗法(NPWT)在烧伤急性期的疗效仍不清楚。近日,发表于Br J Surg的一项双臂单中心RCT研究比较了标准的Acticoat™和Mepitel™敷料与联合Actic

拓展阅读

Plast Reconstr Surg:负压伤口治疗可提高不规则、高活动性区域的植皮取材率

在不规则的、高活动性的区域和不理想的受区伤口中,用于固定皮肤移植的捆绑式栓塞敷料与低移植率有关。负压伤口疗法已成为固定移植物的成熟方法,据报道这种方法的移植物采取率为96.7%。

循证医学证据来了!伤口冲洗该怎么做才更有利于愈合?

最佳伤口护理需要一种以消毒和冲洗为中心的多模式方法。而在临床上伤口冲洗是灵活可变的,并不总以证据为基础。但在循证医学数据的基础上,决定采用何种冲洗方式及灌洗液则是较为科学的决策。

Br J Surg:负压伤口疗法作为儿童小面积热烧伤辅助疗法的有效性

负压伤口疗法(NPWT)在烧伤急性期的疗效仍不清楚。近日,发表于Br J Surg的一项双臂单中心RCT研究比较了标准的Acticoat™和Mepitel™敷料与联合Actic